Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.
Nat Med. 2023 Mar;29(3):646-655. doi: 10.1038/s41591-023-02216-8. Epub 2023 Mar 6.
Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs. Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates (n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor: luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor. Tumor sequencing revealed that left and right tumors (n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view. Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.
双侧同步乳腺癌(sBBC)是指双侧乳房均受到相同的种系遗传学和环境暴露的影响。关于 sBBC 中的免疫浸润和治疗反应,目前证据有限。在这里,我们发现乳腺癌亚型对肿瘤浸润淋巴细胞(TIL,n=277)水平和病理完全缓解(pCR)率(n=140)的影响因对侧肿瘤的乳腺癌亚型是否一致而有所不同:同侧为不一致的腔面型乳腺癌的肿瘤,其 TIL 水平更高,pCR 率也更高。肿瘤测序显示,左右肿瘤(n=20)在体细胞突变、拷贝数改变和克隆进化方面是独立的,而原发性肿瘤和残留疾病在体细胞突变和转录组水平上都有密切的关系。我们的研究表明,肿瘤内在特征可能在肿瘤免疫和 pCR 的相关性中起作用,并表明对侧肿瘤的特征也与免疫浸润和治疗反应相关。